Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2026)

Contineum Therapeutics' Total Current Liabilities history spans 4 years, with the latest figure at $6.7 million for Q1 2026.

  • Quarterly Total Current Liabilities fell 25.61% to $6.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Mar 2026, down 25.61% year-over-year, with the annual reading at $9.7 million for FY2025, 2.31% down from the prior year.
  • Total Current Liabilities came in at $6.7 million for Q1 2026, down from $9.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $10.0 million in Q4 2024 to a low of $3.7 million in Q2 2024.
  • The 4-year median for Total Current Liabilities is $6.5 million (2025), against an average of $7.0 million.
  • Year-over-year, Total Current Liabilities surged 92.94% in 2025 and then dropped 25.61% in 2026.
  • Contineum Therapeutics' Total Current Liabilities stood at $5.5 million in 2023, then surged by 81.87% to $10.0 million in 2024, then decreased by 2.31% to $9.7 million in 2025, then plummeted by 31.68% to $6.7 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Total Current Liabilities are $6.7 million (Q1 2026), $9.7 million (Q4 2025), and $6.4 million (Q3 2025).